JACOBIO-B1167.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, JACOBIO-B (1167.HK) trades at a P/E of 6.93x, P/B of 2.65x, P/S of 4.84x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 12th percentile over the trailing 10Y window (vs. 12th percentile over 3Y); P/B sits at the 39th percentile over the trailing 10Y window (vs. 49th percentile over 3Y); P/S sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 23rd percentile within its industry and the 29th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.92%, ranking at the 97th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 26.8 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. JACOBIO-B operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 1167 · SEHK: 1167 · 1167
Want the full picture on whether JACOBIO-B (1167.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 6.93 | ||||||
| P/B (MRQ) | 2.65 | ||||||
| P/S (TTM) | 4.84 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.92% |